AlphaRx Announces Neuroprotection Research Collaboration with NeuroProtection Inc. and The University Health Network, University of Toronto.Business Editors and Health/Medical Writers RICHMOND HILL, Ontario--(BW HealthWire)--Oct. 25, 2001 AlphaRx Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :AHRX) today announced a research study involving ex-vivo and animal investigations to evaluate different proprietary anti-inflammatory formulations for enhanced delivery effect on site inflammation, brain inflammation, aging and neuroprotection. This study is a collaboration between AlphaRx, NeuroProtection Inc. and the University Health Network, University of Toronto Research at the University of Toronto has been responsible for the world's first electronic heart pacemaker, artificial larynx, single-lung transplant, nerve transplant, artificial pancreas, chemical laser, G-suit, the first practical electron microscope, the first cloning of T-cells, . The principal research study investigator is Dr. Peter Carlen, Professor of Medicine (Neurology) and Physiology at the University of Toronto, and clinical Neurologist/scientist at the Toronto Western Research Institute of the University Health Network. The investigational compounds in this study will include standard Non-Steroidal Anti-Inflammatory Drugs Non-steroidal anti-inflammatory drugs (NSAIDs) Aspirin, ibuprofen, naproxen, and many others. Mentioned in: Mastocytosis (NSAIDs), in combination with AlphaRx's proprietary drug delivery vehicle, and NeuroProtection Inc.'s proprietary membrane-permeable, calcium buffer neuroprotective agents. Part of this research will investigate the neuroprotective activity of AlphaRx's two proprietary anti-inflammatory compounds, code named ARX-2001 and ARX-2002, which have shown low toxicity, rapid onset and prominent anti-inflammatory activity in previous animal studies. The Company believes that these two compounds may have great neuroprotective potential in acute nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency and injuries such as stroke, as well as in chronic neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis and epilepsy, where many of the underlying mechanisms of neural tissue damage are similar. About AlphaRx AlphaRx Inc. is an emerging pharmaceutical company that develops and markets innovative therapeutic products based on its proprietary Bioadhesive Colloidal colloidal of the nature of a colloid. colloidal bath a bath containing gelatin, bran, starch or similar substances, to relieve skin irritation and pruritus. Dispersion (BCD (Binary Coded Decimal) The storage of numbers in which each decimal digit is converted into binary and is stored in a single character or byte. For example, a 12-digit number would take 12 bytes. See binary numbers. ) drug delivery technology. AlphaRx's BCD technology improves the bioavailability bioavailability /bio·avail·a·bil·i·ty/ (bi?o-ah-val?ah-bil´i-te) the degree to which a drug or other substance becomes available to the target tissue after administration. bi·o·a·vail·a·bil·i·ty n. and bioperformance of poorly water-soluble drugs to provide improved medical benefits and competitive commercial advantages. About NeuroProtection Inc. NeuroProtection Inc. (NPI NPI National Provider Identifier, see there ) is a drug development company specializing in the discovery and development of neuroprotective compounds. NPI houses proprietary property in membrane-permeant calcium buffers targeted at neuroprotection and aging. NeuroProtection Inc. also provides novel drug screening services for the identification of neuroprotective therapeutic candidates in compound libraries. About Toronto Western Research Institute Toronto Western Research Institute (TWRI TWRI Toronto Western Research Institute TWRI Through-The-Wall Radar Imaging ) is one of the three research institutes comprising the University Health Network (UHN). TWRI is home to the research programs associated with the neural and visual sciences, musculoskeletal disease and urban and community health priority programs at UHN. Neuroscientists at TWRI explore the function of the nervous system as they develop treatments for spinal cord injuries, cerebral ischemia, vascular malformations, brain tumours, neurophthalmologic disorders and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. FORWARD LOOKING STATEMENTS: This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion